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Alcohol-induced liver injury (ALI) has been associated with,
among other molecular changes, abnormal hepatic methionine
metabolism, resulting in decreased levels of S-adenosylmethionine
(SAM). Dietary methyl donor supplements such as SAM and
betaine mitigate ALI in animal models; however, the mechanisms
of protection remain elusive. It has been suggested that methyl
donors may act via attenuation of alcohol-induced oxidative
stress. We hypothesized that the protective action of methyl
donors is mediated by an effect on the oxidative metabolism of
alcohol in the liver. Male C57BL/6J mice were administered
a control high-fat diet or diet enriched in methyl donors with or
without alcohol for 4 weeks using the enteral alcohol feeding
model. As expected, attenuation of ALI and an increase in
reduced glutathione:oxidized glutathione ratio were achieved with
methyl donor supplementation. Interestingly, methyl donors led to
a 35% increase in blood alcohol elimination rate, and while there
was no effect on alcohol metabolism in the stomach, a profound
effect on liver alcohol metabolism was observed. The catalase-
dependent pathway of alcohol metabolism was induced, yet the
increase in CYP2E1 activity by alcohol was blunted, which may be
mitigating production of oxidants. Additional factors contributing
to the protective effects of methyl donors in ALI were increased
activity of low- and high-Km aldehyde dehydrogenases leading to
lower hepatic acetaldehyde, maintenance of the efficient mito-
chondrial energy metabolism, and promotion of peroxisomal
b-oxidation. Profound changes in alcohol metabolism represent
additional important mechanism of the protective effect of methyl
donors in ALI.
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Hepatic methionine metabolism, also referred to as one-
carbon metabolism, is critical for a number of vital liver
functions. One of the most important roles is the production of
S-adenosylmethionine (SAM), the principal methyl donor
required for the methylation of DNA, RNA, proteins, and
phospholipids and as a precursor for polyamine and reduced
glutathione (GSH) synthesis. Increasing evidence has shown
that deficiencies or impairment of this pathway can contribute
to the pathogenesis and progression of liver disease (Mato and
Lu, 2007). Experimental animal models using diets deficient in
methyl donors, such as methionine or choline, result in the
spontaneous development of nonalcoholic steatohepatitis (Oz
et al., 2008) and hepatocellular carcinoma (HCC) (Shivapurkar
and Poirier, 1983). Interestingly, the methionine adenosyl-
transferase (Mat1a) knockout mouse model that results in the
chronic depletion of SAM and the glycine N-methyltransferase
(Gnmt) knockout mouse model that results in the over-
production of SAM (Luka et al., 2006) both promote
steatohepatitis (Lu et al., 2001; Mato and Lu, 2007) and
HCC (Martinez-Chantar et al., 2002; Tseng et al., 2003). These
observations suggest that SAM is tightly regulated and should
be well balanced in order to maintain liver physiological
function.
Aberrant hepatic methionine metabolism is commonly
observed in patients with alcoholic liver disease. Both
decreases in SAM and folate (Cravo et al., 1996) and
elevations in homocysteine (de la Vega et al., 2001) in liver
or serum samples have been reported. This condition is
multifactorial in origin and results not only from poor nutrition
but also due to the deleterious effects of alcohol on intestinal
absorption and hepatic uptake of essential amino acids and B
vitamins necessary to support one-carbon metabolism (Halsted
et al., 1973). Moreover, the oxidative metabolism of alcohol
resulting in changes in the hepatic redox state shifts the cycle
away from recycling methionine for SAM production to
synthesizing the antioxidant glutathione.
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The use of dietary methyl donor supplementation in patients
with alcoholic cirrhosis has produced mixed results (Mato et al.,
1999; Vendemiale et al., 1989). Only one clinical study reported
improved survival with long-term dietary supplementation with
SAM alone but only among those with less advanced liver
disease (Mato et al., 1999). Thus, better understanding of the
mechanisms underlying the linkages between one-carbon
metabolism and alcohol-induced liver injury (ALI), especially
the protective effects of dietary supplementation with methyl
donors, is needed. In this study, unlike previous works to date
that have employed single nutritional supplements, we have
used a combination of methionine and its metabolites (choline,
betaine, and folate), as well as cofactors (vitamins B6, B12, and
zinc), to fortify one-carbon metabolism in the liver. We report
that the protective effects are mediated via profound changes in
alcohol metabolism and describe the mechanistic underpinnings
of this effect.
MATERIALS AND METHODS
Animals, diets, and treatment. Male C57BL/6J mice (8 weeks old;
Jackson Laboratory, Bar Harbor, ME) were randomized into two groups and
provided either a standard (Isopro RMH 3000; Lab Diet, Richmond, IN) or
methyl-enriched (TD.01310; Harlan-Teklad, Madison, WI) rodent chow for
1 week prior to and immediately following surgical intragastric intubation until
the intragastric feeding was initiated (Kono et al., 2000). Following surgery,
mice were housed in individual metabolic cages and allowed a week to recover
with ad libitum access to food and water. Following the recovery period, mice
were administered via gastric cannula high-fat diets (HFDs) prepared as
detailed in Thompson and Reitz (1978), which contained either maltose-dextrin
(isocaloric control, referred to as ‘‘control’’) or ethyl alcohol (referred to as
‘‘alcohol’’) with or without methyl donor enrichment (added per kilogram diet:
15 g betaine, 13.2 g choline chloride, 13.6 mg folic acid, 7.5 g L-methionine,
0.13 mg vitamin B12, and 648 mg zinc sulfate). The high-fat (corn oil–based)
diet is necessary to facilitate the development of steatohepatitis in this animal
model of ALI (Nanji et al., 1989). Alcohol was delivered initially at 17.3 g/kg/
day and was gradually increased to 1.3 g/kg every 2 days until day 8. The dose
was then incrementally adjusted 1 g/kg every 4 days until the dose reached
27 g/kg/day. 5-bromo-2#-deoxyuridine (BrdU) was administered in the diet
(0.02 ml/g) the last 3 days of the experiment. Mice were monitored four times
daily throughout the study and sacrificed after 28 days of treatment. There were
five to seven mice per experimental group at the end of these experiments. In
parallel experiments, which assessed alcohol elimination rates, mice were either
provided a standard or methyl-enriched rodent chow (see above) for 2 weeks
and administered a single bolus (1.5 g/kg) of alcohol by gavage in saline
vehicle (20% dilution) or treated with alcohol in a HFD (with or without methyl
donor supplementation) via gastric cannulation exactly as described above for
8 days. In both experiments, tail vein blood samples were collected at 30-min
intervals for 2.5 h after alcohol dosing. All animals were given humane care in
compliance with National Institutes of Health guidelines, and this work was
approved by the institutional animal care and use committee.
Histopathology. Formalin-fixed paraffin-embedded liver or kidney sec-
tions (6 lm) were stained with hematoxylin/eosin (H&E) or periodic acid
Schiff (PAS) stain, respectively, for light microscopy evaluation of liver or
kidney pathology. H&E-stained slides were scored as described by Nanji et al.
(1989) as follows: steatosis (the percentage of hepatocytes containing fat): <
25% ¼ 1þ, < 50% ¼ 2þ, <75% ¼ 3þ, and > 75% ¼ 4þ; inflammation and
necrosis: one focus per low-power field ¼ 1þ and two or more foci ¼ 2þ.
PAS-stained slides were scored as follows: þ, slight and focal lesions (less than
30% of area effected); 2þ, moderate and diffuse lesions (30–70% effected); and
3þ, severe and massive lesions (more than 70% effected).
Immunohistochemical detection of BrdU. Formalin-fixed paraffin-
embedded liver sections (6 lm) were mounted on glass slides. Sections were
deparaffinized and rehydrated, and immunodetection was performed using
DAKO EnVision System HRP (DakoCytomation, Carpinteria, CA) with
primary anti-BrdU monoclonal antibody (clone Bu20a; DAKO) diluted in PBS
containing 1% bovine serum albumin and incubated overnight at 4C.
Quantitative analysis was performed by averaging percent positively stained
nuclei to total nuclei within 10 random fields at 3200.
Clinical chemistry. Alcohol and acetaldehyde concentrations in serum,
urine, or liver tissue homogenates were determined as described elsewhere
(Bergmeyer, 1988). Serum alanine aminotransferase (ALT) levels were
determined spectrophotometrically with the Thermo Scientific Infinity ALT
Liquid stable reagent (Thermo Electron, Melbourne, Australia).
Determination of aminothiols. The content of one-carbon metabolites in
liver tissue extracts was determined using high-performance liquid chroma-
tography with coulometric electrochemical detection as previously described
(Trasler et al., 2003).
Protein level and activity measurements. Cytosol, membrane, mitochon-
drial, and nuclear proteins were obtained by subcellular fractionation of liver
tissue using the Qproteome Cell Compartment Kit (Qiagen, Valencia, CA).
Proteins were resolved using 4–12% Bis-Tris gradient gel electrophoresis
(Invitrogen, Carlsbad, CA) and transferred to 0.45-lm polyvinylidene
difluoride membranes (Invitrogen) by electroblotting. Membranes were blocked
in 5% nonfat dry milk in PBS-T (0.1% Tween 20 in PBS); probed with 1 lg/ml
anti-alcohol dehydrogenase (ADH) (Abcam, Cambridge, MA), 1:1000 anti-
Cyp2e1 (Biomol, Plymouth Meeting, PA), 0.25 lg/ml anti-catalase (Calbio-
chem, San Diego, CA), 0.5 lg/ml anti-aldehyde dehydrogenase (ALDH)1
(Calbiochem), 1 lg/ml anti-ALDH2 (Santa Cruz Biotechnology, Santa Cruz,
CA), or 1 lg/ml anti-peroxisome proliferator–activated receptor (PPAR)a
(Abcam); and incubated overnight at 4C. Blots were then washed in Tris-
Buffered Saline Tween-20, incubated with the appropriate secondary anti-
body, and detected using chemiluminescence Western blotting analysis kit
(Amersham, Pittsburgh, PA). Experiments were repeated two to three times,
and representative blots are shown. The ‘‘ADH activity’’ assay was modified
from a method described elsewhere (Crow et al., 1977) for 96-well plate
format. Enzyme activity was determined based on the linear decline in
absorbance at 340 nm resulting from the reduction of nicotinamide adenine
dinucleotide (NADþ) by ADH per milligram protein. ‘‘Cyp2e1 activity’’ was
measured by the rate of hydroxylation of p-nitrophenol to p-nitrocatechol by
isolated hepatic microsomes (Koop, 1986). The ‘‘peroxidatic function of
catalase’’ was measured using the catalase kit (Cayman Chemical Company,
Ann Arbor, MI) according to manufacturer’s protocol. The activity of the
peroxisomal enzyme, ‘‘acyl-CoA oxidase,’’ was measured as previously
described (Inestrosa et al., 1979) and modified for 96-well format. To measure
‘‘ALDH activity,’’ liver or kidney S9 fractions were diluted in buffer containing
50mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 8.4) and
0.33 mM dithiothreitol. For high-Km ALDH activity (ALDH1), fractions were
added to a reaction mixture containing 0.1mM pyrazole, 5 mM acetaldehyde,
and 0.5 mM NADþ in 50 mM sodium pyrophosphate buffer (pH 8.8). Samples
for low-Km ALDH (ALDH2) were sonicated for 10 s prior to analysis. ALDH2
activity was measured as described for ALDH1 except 0.1 mM acetaldehyde,
and the addition of 2 lM rotenone was used. Activity was determined by
monitoring the reduction of NADþ by ALDH at 340 nm. Chymotrypsin-like
activity or trypsin-like ‘‘activity of the proteasome’’ was determined with
fluorogenic synthetic peptides, Suc-LLVY-AMC, or LSTR-AMC, respectively
(Donohue et al., 2004).
Hepatic acetaldehyde content. Levels of acetaldehyde were determined in
liver supernatants as described in Bergmeyer (1988) and modified for use in a 96-
well plate format. Samples of liver supernatant were incubated for 1 h in buffer
containing 1M KCl, 0.5M Tris (pH 7.0), 47mM 2-mercaptoethanol, 1.5mM
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NADþ, and 0.13 mg/ml ALDH (Sigma-Aldrich) in a ratio of 10:1 buffer:sample
or standard. The reduction of NADþ by ALDH was measured at 340 nm.
Acetaldehyde concentrations were determined from a standard curve of known
amounts of acetaldehyde (0–89lM) and were normalized to protein content.
Nuclear magnetic resonance–based serum metabolite analysis. To each
40 ll aliquot of serum, 60 ll of 200mM formate and 500 ll H2O with 0.02%
NaN3 was added and transferred to 5-mm nuclear magnetic resonance (NMR)
tubes. The formate was added as a chemical shift reagent as well as internal
standard with a final concentration of 20mM. NMR spectra were acquired on
a Varian Inova 400 MHz (Varian, Inc., Palo Alto, CA) as detailed previously
(Bradford et al., 2008). The bins containing alcohol were removed from all
spectra, and bins were renormalized. Profiling of the metabolites was carried out
using the Chenomx NMR metabolite database (Chenomx Inc., Edmonton,
Canada). Confirmation of assignments was aided by two-dimensional (1H-13C)
experiments on selected samples. Statistical analysis was performed using
SimcaPþ v.11.5 (Umetrics, Umea, Sweden).
RESULTS
Methyl Donor–Enriched Diet Attenuates Alcohol-Induced
Steatohepatitis
All mice gained weight throughout the study; however, mice
on methyl donor–enriched diets gained ~10% less weight than
those in high-fat control group (Table 1, Supplementary fig. 1).
Increased liver-to-body weight ratios were also observed in
HFD þ alcohol group, of which a fatty liver and increased
hepatocyte proliferation (Table 1) are likely contributing
factors. Liver-to-body weight ratios and proliferation rates in
the methyl donor high-fat diet (MDHFD) þ alcohol group were
not different from controls. Mild inflammation was observed
in livers of mice of all groups (Fig. 1, Table 1). Pronounced
steatohepatitis, as evidenced by macrovesicular and micro-
vesicular steatosis, necrosis, and inflammation (Fig. 1B,
Table 1), was observed in liver sections from mice in the
HFD þ alcohol group. In sharp contrast, mice in the MDHFD þ
alcohol group showed remarkably reduced appearance of
fatty liver and no signs of necrosis (Fig. 1D, Table 1). No
appreciable kidney toxicity was observed in this study
(Supplementary table 3).
Rate of Alcohol Metabolism Is Increased by a Methyl Donor–
Enriched Diet
Rodents fed alcohol continuously exhibit a cyclic fluctuation
in urine alcohol concentrations (UAC) due to diurnal variation
in basal metabolism and hormones (Li et al., 2000). In animals
receiving HFD þ alcohol, cyclic oscillations in UAC occurred
approximately every 8 days, with concentrations ranging
between 50 and 600 mg/dl, despite constant steady increase
in the dose of alcohol (Fig. 2). However, in animals receiving
MDHFD þ alcohol, the cyclic oscillation in UAC was
profoundly blunted with peak and trough concentrations
fluctuating only between 250 and 50 mg/dl. The net result of
this was an approximately twofold reduction in the mean daily
UAC even though blood and liver alcohol concentrations at
sacrifice were high (Table 1). Since these data infer that the
rate of alcohol metabolism is increased in methyl donor–
supplemented animals, blood alcohol elimination (BAE) rates
were determined by measuring blood alcohol concentration
every hour over 6-h time period on day 8 of treatment as the
first peak in UAC begins to fall. A 35% increase in BAE rate
TABLE 1
Effect of Methyl Donor–Enriched Diet on Routine Clinical
Parameters
HFD MDHFD
Control Alcohol Control Alcohol
Steatosis score 0 2.8 ± 0.3a,d 0 0.9 ± 0.4
Inflammation score 1.7 ± 0.3 1.1 ± 0.1 1.5 ± 0.3 1.2 ± 0.3
Necrosis score 0.7 ± 0.4 1.7 ± 0.3d 0 0
Total pathology score 2.3 ± 0.6 5.6 ± 0.5a,d 1.5 ± 0.3 2.1 ± 0.4
ALT (U/l) 16 ± 4 76 ± 26 14 ± 2 28 ± 7
BAC (mg/dl) 24 ± 5 194 ± 61a,c 30 ± 5 239 ± 36a,c
LAC (lg EtOH/lg protein) 11 ± 1 22 ± 5a,c 8 ± 1 17 ± 2a,c
UAC (mg/dl) 23 ± 9 338 ± 102a,c 20 ± 8 175 ± 44a,c
Mean daily UAC (mg/dl) 23 ± 2 225 ± 34a,c,d 16 ± 1 123 ± 17a,c
BAE rate (mg/kg/h) ND 395 ± 89 ND 535 ± 111b
Terminal body weight (g) 28 ± 1 26 ± 1 25 ± 0a 23 ± 1a,b
Terminal liver weight (g) 1.9 ± 0.1 2.3 ± 0.1 1.5 ± 0.1a 1.4 ± 0.0a,b
% Liver:body weight 6.8 ± 0.5 8.6 ± 0.4a,c,d 6.1 ± 0.1 6.0 ± 0.2
Proliferation (% BrdU) 0.1 ± 0.2 10.9 ± 5.4a 3.6 ± 2.4 3.8 ± 0.7
Notes. Values given are mean ± SEM (n ¼ 5–7). Statistical significance of
means was determined using Mann-Whitney rank sum test for histopathology
scores, while one-way ANOVA followed by Tukey’ post hoc test were used for
all other measurements. Significance (p < 0.05) is indicated in bold and by an
asterisk when compared to (a) HFD control, (b) HFD þ alcohol, (c) MDHFD, or
(d) MDHFD þ alcohol. ALT, alanine aminotransferase; BAC, blood alcohol
concentration; LAC, liver alcohol concentration; ND, not determined.
FIG. 1. Attenuation of ALI in mice administered methyl donor–enriched
HFD. Male C57BL/6J mice were administered a control HFD (A and B) or
methyl donor–enriched HFD (C and D) with (B and D) or without (A and C)
alcohol for 4 weeks using an intragastric feeding protocol. Representative
photomicrographs of H&E-stained liver sections from mice administered
various types of treatments as indicated; original magnification 3100.
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was observed in mice given MDHFD þ alcohol over those
receiving HFD þ alcohol (Table 1).
Methyl Donor–Enriched Diet Has No Effect on First-Pass
Metabolism of Alcohol
Although many tissues can metabolize alcohol, considerable
metabolism occurs in the liver and, to a lesser extent, in the
stomach. The lack of liver injury along with reduced UAC and
increase in BAE rate in mice given MDHFD þ alcohol could
lead one to speculate that increased metabolism of alcohol in
the stomach prevented significant quantities of alcohol reach-
ing the liver. Stomach catalase/D-amino acid oxidase pathway
has been shown to be partially responsible for the protective
action of glycine on ALI (Iimuro et al., 1996). To address the
role of first-pass metabolism in the protection afforded by
the methyl donor–enriched diet, we assessed the activity of
stomach ADH and catalase in mice fed the diets for 28 days
and observed no differences between control and methyl
donor–enriched diet groups (Supplementary table 1). In
addition, disposition of alcohol after a single acute dose was
unaffected by methyl donors when mice were fed ad libitum
with a pelleted control or methyl donor–enriched diet for
2 weeks followed by an oral bolus (1.5 g/kg) of alcohol (data
not shown).
Methyl Donor–Enriched Diet Leads to Stimulation of the
Catalase-Dependent Alcohol Metabolism in the Liver
During moderate alcohol consumption, the majority of
alcohol is metabolized to acetaldehyde by ADH in the liver, but
under conditions of chronic high-dose exposures, a significant
portion is metabolized by the catalase-peroxide complex and,
to a lesser degree, Cyp2e1. Thus, hepatic activity of all three
enzymes was measured in this study. ADH activity was found
to be marginally, but not significantly, increased in both
alcohol-treated groups, and no effect of the methyl donors was
observed (Fig. 3A). While Cyp2e1 activity (Fig. 3B) and
protein levels (Fig. 3D) were significantly elevated in both
alcohol-fed groups, the induction in MDHFD þ alcohol group
was significantly lower than that in HFD þ alcohol group.
FIG. 2. Representative plots of daily UAC. Typical urine alcohol levels in
mice administered different diets as indicated. The dose of alcohol administered
over the 28 days of treatment is plotted on the right y-axis.
FIG. 3. Liver alcohol metabolism. Liver activity of (A) ADH, (B) Cyp2e1, and (C) catalase was determined in mice administered a control HFD or MDHFD
with or without alcohol for 4 weeks. Asterisks indicate statistically significant (**p < 0.01 and ***p < 0.001) differences using one-way ANOVA followed by
Tukey’s post hoc test. N ¼ three to five animals per group. (D) Representative Western blots for ADH, catalase, and Cyp2e1. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and cadherin were used for cytosol and membrane protein loading controls, respectively.
134 POWELL ET AL.
Interestingly, activity of catalase was increased significantly in
mice given a MDHFD þ alcohol compared to all other groups
(Fig. 3C) even though protein levels did not change
significantly (Fig. 3D). The activity of acyl-CoA oxidase,
enzyme that provides hydrogen peroxide needed for catalase-
dependent alcohol metabolism, was also significantly increased
only in the MDHFD þ alcohol group (Fig. 4C). Since
acyl-CoA oxidase is controlled by PPARa, we also assessed
liver (nuclear) protein levels of PPARa (Fig. 4A) and
expression of CYP4A10 (Fig. 4B), a PPARa-controlled
gene. All were induced significantly in the MDHFD þ alcohol
group.
Methyl Donor–Enriched Diet Reduces Hepatic Acetaldehyde
Content
Alcohol metabolism results in the production of acetalde-
hyde, a reactive metabolite, which in turn is rapidly metabolized
to acetate by ALDH. The activity of liver ALDH1 and 2 in the
MDHFD þ alcohol group was statistically different from all
other groups (Fig. 5A), and protein levels for ALDH1 and
ALDH2 were increased (Fig. 5B). Although liver ALDH2
protein content was also increased in mice given HFD þ
alcohol (Fig. 5B), it did not result in an increase in enzyme
activity (Fig. 5A). Kidney activity of ALDH1 and 2 was much
lower than that in the liver, and little effect of the methyl donor
supplementation was observed (Supplementary fig. 2). Striking
differences in hepatic acetaldehyde content were also observed
between two alcohol-fed groups. Levels in mice given HFD þ
alcohol were eightfold higher than those receiving MDHFD þ
alcohol (Fig. 5C). Hepatic acetaldehyde content was determined
to also strongly correlate with liver injury (Fig. 5D).
Effect of MDHFD on Hepatic One-Carbon Metabolism
Methyl donor–enriched diets were formulated to provide
substantially increased amounts of cofactors (Cooney, 1993).
Indeed, in both MDHFD and MDHFD þ alcohol–treated mice,
hepatic levels of SAM were significantly increased by 10- to
20-fold, respectively (Table 2). SAM:S-adenosylhomocysteine
(SAH) ratios, an indicator of transmethylation potential, were
also considerably improved fivefold to sevenfold. Homocys-
teine, a metabolic by-product of SAM methylation reactions, is
typically methylated to regenerate methionine but during
conditions of oxidative stress is diverted for GSH production.
HFD þ alcohol treatment reduced the levels of GSH and raised
the levels of oxidized glutathione (GSSG) while reducing the
GSH:GSSG ratio, an index of overall oxidant stress. MDHFD þ
alcohol treatment did not increase GSH but reduced the levels
of GSSG.
Methyl Donors Affect Cellular Energy Metabolism
Analysis of the serum metabolome determined that feeding
a methyl donor–enriched diet results in changes in carbohy-
drate and lipid metabolism following alcohol treatment
(Fig. 6). Levels of acetate and citrate were reduced in mice
given MDHFD þ alcohol compared to those receiving HFD þ
alcohol, a condition that would preferentially stimulate
carbohydrate metabolism over fatty acid oxidation. Lipid
metabolism, however, appeared to be stimulated in mice given
MDHFD þ alcohol as serum lipids and, in particular very low–
density lipoprotein, were found to be elevated.
FIG. 4. Activation of PPARa pathway in mice administered methyl
donor–enriched HFD and alcohol. (A) Fold change in liver levels (nuclear
extracts) of PPARa in mice administered a control HFD or MDHFD with or
without alcohol for 4 weeks. TATA expression was used as control. (B) Fold
change in expression of Cyp4a10 was derived using 2DDCt values and
normalized to expression of the housekeeping gene Gusb. (C) Liver activity of
acyl-CoA oxidase. Asterisks indicate statistically significant (***p < 0.001)
differences using one-way ANOVA followed by Tukey’s post hoc test. N ¼
three to five animals per group.
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DISCUSSION
The association between decreased hepatic SAM content and
the severity of alcoholic hepatitis in humans, a well-established
phenomenon (Herbert et al., 1963), has prompted studies of
methyl donors in a variety of animal models of ALI.
Administration of diets deficient in methionine, choline, or
folate or combinations thereof to rats, mice, or mini-pigs have
been shown to exacerbate ALI (Gyamfi et al., 2008). To the
contrary, dietary supplementation with SAM or betaine to
alcohol-fed rats (Garcia-Ruiz et al., 1995) or baboons (Lieber
et al., 1990) attenuated liver injury, restored GSH, and
improved mitochondrial function. Several hypotheses have
been proposed to explain the mechanism of protection offered
by methyl donors, including attenuation of oxidative stress by
restoring levels of GSH (Garcia-Ruiz et al., 1995), an increase
in SAM:SAH ratio (Barak et al., 1993), and an attenuated
inflammatory response (Song et al., 2007). It is likely that these
mechanisms are interdependent, yet the causality and tempo-
rality are not well understood.
In this study, the expected attenuation of ALI (e.g.,
restoration of the liver glutathione balance and attenuation of
liver injury phenotypes) by dietary methyl donor supplemen-
tation was achieved in a subchronic mouse model and known
hallmarks of methyl donor’s protective effects (Purohit et al.,
2007) were observed. While it is without a doubt that
upregulation of the transsulfuration pathway, which leads to
a decrease in oxidative stress via increased synthesis of
glutathione, is a major contributor to protection, our data
suggest a novel mechanism via the effect on alcohol
metabolism in the liver.
Through observations of the daily changes in the urinary
alcohol content, we detected an effect of the methyl donor–
enriched diet on the oxidative metabolism of alcohol.
Importantly, it has been reported that SAM accelerates the
clearance of alcohol and acetaldehyde in humans (di Padova
et al., 1984), but no mechanism for this effect was proposed.
Thus, the phenotype studied here in the mouse model of ALI is
relevant to clinical practice.
We found that a 35% increase in BAE rate in methyl donor–
supplemented animals was due to changes in liver metabolism but
not due to first-pass metabolism in the gut. Interestingly, the most
pronounced effect of methyl donor supplementation was the
induction of the catalase-dependent pathway since increased
activity of both catalase and acyl-CoA oxidase, source of
hydrogen peroxide necessary for catalase function, was observed.
Not only was alcohol metabolism enhanced through this
route but also the activity of low- and high-Km ALDH was also
FIG. 5. Liver acetaldehyde content is reduced by methyl donor–enriched
diet following subchronic alcohol exposure. Activity (A) and protein content
(B) for ALDH1 and 2 were assessed in mice administered a control HFD or
MDHFD with or without alcohol for 4 weeks. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) and Tim23 were used as cytosol and mitochondrial
loading controls, respectively. (C) Acetaldehyde content in liver. (D) Semi-log
correlation plot of acetaldehyde content with total pathology score (Spearman
r2 ¼ 0.71). Asterisks indicate statistically significant (*p < 0.05 and **p <
0.01) differences using one-way ANOVA followed by Tukey’s post hoc test.
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increased, which created favorable conditions for fast and
efficient catabolism of alcohol and lower liver levels of
acetaldehyde, a highly cytotoxic molecule and a key mediator
of liver injury by alcohol (Seitz and Stickel, 2007). The effect of
methyl donor supplementation on alleviating the net levels of
acetaldehyde produced during feeding with alcohol is a
potentially important part of the protection against ALI. Indeed,
in humans, SAM was shown to favor the elimination of alcohol
without increasing blood levels of acetaldehyde (di Padova
et al., 1984).
It is not known, however, how SAM and/or other methyl
donors can activate catalase and acyl-CoA oxidase, a potential
means through which the methyl donor–supplemented diet
appears to exhibit its protective action against ALI in the
mouse. One possible mechanism could be through epigenetic
regulation as it was suggested that the degree of methylation of
the CpG-rich promoter of the catalase gene may be important
for regulation of its expression (Reimer et al., 1994). In
addition, it is plausible that a higher order regulatory
mechanism that may affect both catalase and acyl-CoA oxidase
is involved. A potential key pathway may be through PPARa,
which controls expression of both proteins of interest, since
induction of Cyp4a10 was also observed in the same group.
Indeed, we observed that methyl donor supplementation led to
an increase in nuclear protein levels for PPARa. It was
suggested that SAM may act through a putative RNA
methyltransferase PIMT (PPAR-interacting protein with meth-
yltransferase domain) to enhance the transcriptional activity of
both PPARs and retinoid-X-receptors (Zhu et al., 2001). Since
in our study the marked elevations in liver methionine and
SAM were detected in livers of methyl donor–supplemented
mice, in both control and alcohol-treated groups, it is plausible
that this mechanism may be responsible for an increase in
nuclear levels of PPARa.
Alcohol may impair PPARa-dependent signaling in the
liver, which is an important factor in deregulation of lipid and
overall metabolism, thus contributing to the development of
ALI. Specifically, evidence exists that ALI is exacerbated in
Ppara-null mice (Nakajima et al., 2004) and that PPARa
agonists are protective against ALI (Fischer et al., 2003).
Alcohol is also known to lead to a decrease in liver Ppara
messenger RNA and protein as well as reduced expression of
PPARa-controlled genes, such as acyl-CoA oxidase (Fischer
et al., 2003; Lu et al., 2008). Our data suggest that methyl
donors are able to block this deleterious effect of alcohol by
activating PPARa and/or supporting peroxisomal and mito-
chondrial metabolism (see below), resulting in activation of
catalase-dependent alcohol metabolism. It should be noted that
the modest but significant activation of PPARa in methyl
donor–enriched HFD group had no observable effect on
alcohol metabolism, activity of acyl-CoA oxidase, or Cyp4a10
expression, which suggests that additional factors, such as
increased stability of the enzymes (Horie and Suga, 1990), may
be responsible for the overall protective effect.
We also observed that alcohol-induced activation of Cyp2e1,
a protein that is known to contribute to liver oxidative stress
(Lu and Cederbaum, 2008), was blunted by methyl donors.
TABLE 2
Effect of Methyl Donor–Enriched Diet on Hepatic One-Carbon
Metabolism
HFD MDHFD
Control Alcohol Control Alcohol
Methionine metabolism
Methionine 1.0 ± 0.12 0.8 ± 0.05 5.0 ± 0.94 12.1 ± 2.95a,b,c
SAM 0.3 ± 0.05 0.1 ± 0.02 2.2 ± 0.41a,b 4.3 ± 0.27a,b,c
SAH 0.2 ± 0.03 0.2 ± 0.02 0.5 ± 0.07a,b 0.6 ± 0.03a,b
SAM:SAH 1.4 ± 0.19 0.8 ± 0.14 5.3 ± 1.51a,b 7.1 ± 0.52a,b
Adenosine 0.7 ± 0.04 0.6 ± 0.07 0.5 ± 0.06 0.5 ± 0.02
Homocysteine 0.2 ± 0.02 0.2 ± 0.01 0.1 ± 0.01 0.2 ± 0.01
Glutathione biosynthesis
Cysteine 11 ± 1.1 9 ± 1.1 8 ± 0.5 9 ± 0.2
Glu-Cys 0.12 ± 0.02 0.23 ± 0.03 0.12 ± 0.02 0.13 ± 0.02
GSH 84 ± 3 42 ± 4a,c 73 ± 8 60 ± 2
GSSG 0.49 ± 0.12 0.82 ± 0.10a,c,d0.28 ± 0.09 0.22 ± 0.02
GSH:GSSG 191 ± 43 55 ± 12c,d 321 ± 92 277 ± 36
Cys-Gly 1.2 ± 0.09c,d 1.2 ± 0.11c,d 0.23 ± 0.03 0.41 ± 0.05
Notes. Metabolite concentrations (nanomoles per milligram protein) were
measured in liver tissue homogenates using coulometric electrochemical high-
performance liquid chromatography detection as described in Materials and
Methods section. Values given are the mean ± SEM from (n ¼ 5–7 mice).
Significance of the difference in means (p < 0.05, one-way ANOVA followed
by Tukey’s post hoc test) is indicated by bold font and by an asterisk when
compared to (a) HFD control, (b) HFD þ alcohol, (c) MDHFD, or (d) MDHFD
þ alcohol. Cys-Gly, cysteinylglycine; Glu-Cys, glutaminecysteine.
FIG. 6. Alterations in serum metabolites by methyl donors and alcohol.
Metabolites in serum from mice (three per group) given a control HFD or
MDHFD with or without alcohol for 4 weeks. Heatmap of metabolites
significantly different (one-way ANOVA, p < 0.05) between two alcohol-
treated groups is shown. Values are log2 transformed and median centered and
metabolites clustered using average linkage–centered correlation. A complete
list of metabolite data is available in Supplementary table 2.
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While SAM is known to be a weak inhibitor of Cyp2e1 (Caro
and Cederbaum, 2005), the Ki for inhibition is relatively high,
and it is not likely that a direct effect of SAM on Cyp2e1 was
responsible for the effect observed here. Interestingly, a similar
protective effect on Cyp2e1 activation by alcohol was reported
recently with betaine (1% in drinking water for 2 weeks)
supplementation (Kim et al., 2008). The increase in Cyp2e1
protein levels and activity in the liver following treatment with
alcohol is due to reduced protein turnover by the ubiquitin-
dependent proteasomal pathway (Morishima et al., 2005) and
not due to increased transcription. While blunted activation of
Cyp2e1 in mice given MDHFD þ alcohol was associated with
remarkably higher proteasome activity as compared to HFD þ
alcohol group, we did not observe an inhibition of proteasome
with alcohol in this mouse model (data not shown). Nonethe-
less, a blunted increase in Cyp2e1 activity in methyl donor
diet þ alcohol group may be an important factor for alleviation
of liver injury by way of prevention of the formation of
cytotoxic reactive oxygen species and lipid peroxides.
Pathogenesis of alcohol-induced hepatic steatosis and steato-
hepatitis is thought to be dependent on oxidative stress,
whereby lipid peroxidation products facilitate the inflammatory
response (Day and James, 1998).
The metabolomic analysis suggested that additional factors
contributing to the protective effects of methyl donors in ALI
may be the improved maintenance of the efficient mitochon-
drial energy metabolism and promotion of peroxisomal
b-oxidation of fatty acids. It is known that folate is responsible
for stimulating methyl transfer pathways in the cytosol and
mitochondria (Depeint et al., 2006). Indeed, serum acetate,
a key transmitochondrial membrane shuttle, was lower in
the mice fed methyl donors and alcohol compared to alcohol
group without supplementation, suggesting that mitochon-
drial function may be improved. In addition, methionine was
found to be markedly elevated in serum of mice fed methyl
donors and alcohol. Methionine and its metabolite carnitine
play an important role in shuttling long-chain fatty acids
into the mitochondrial matrix. Even though the elevation of
serum carnitine in this group was not significant, it is evident
that adequate levels were present in the liver to facilitate
b-oxidation of fatty acids and dampen the untoward effects of
alcohol on fatty acid metabolism. In view of our suggestion
that a PPARa-related alcohol metabolism pathway may be
induced by methyl donor supplementation, it is noteworthy that
Makowski et al. (2009) demonstrated that PPARa is a regulator
of carnitine levels and that Ppara-null mice have lower levels
of carnitine and fasted ketone levels suggestive of lowered
rates of b-oxidation.
SUPPLEMENTARY DATA
Supplementary data are available online at http://toxsci
.oxfordjournals.org/.
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